GlassScriptPhysician profile
Marc T Nuttall
NPI 1144497322
$11,699.22
in general payments reported to CMS, 2019-2025
68 companies · $2,204 in 2025
The $2,204 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,694 · 2020: $539 · 2021: $269 · 2022: $1,331 · 2023: $2,581 · 2024: $2,080 · 2025: $2,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,138 · Education: $368 · Honoraria: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,137.68 |
| Education | $367.95 |
| Honoraria | $360.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $860.46 | 2019-2025 | |
| Pfizer INC. | $850.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $791.60 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Daiichi Sankyo INC. | $729.42 | 2019-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $593.79 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Janssen Biotech, INC. | $550.81 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Amgen INC. | $472.23 | 2019-2023 | Kyprolis, Evenity, Prolia |
| Merck Sharp & Dohme LLC | $405.24 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Emd Serono, INC. | $404.83 | 2019-2025 | Bavencio |
| Bayer Healthcare Pharmaceuticals INC. | $333.71 | 2019-2025 | |
| Eisai INC. | $331.98 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $327.59 | 2019-2025 | Opdivo, Opdualag |
| Gilead Sciences, INC. | $282.89 | 2019-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $280.63 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Lilly USA, LLC | $262.07 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Nuttall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.